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Highlights 
 Trend data from DFSA cohort studies is reported for the first time. 
 Why certain compounds are detected in the DFSA cases is explored in detail.  
 The  mechanism of action of drugs associated with DFSA is reported. 
 Attempt is made to identify compounds more likely to be used in predatory DFSA. 
 A critical multifactorial review of compounds detected in DFSA cases is included. 
 
Abstract 
Drug-Facilitated Sexual Assault (DFSA) is a sexual act in which the victim is unable to give or 
rescind consent due to intoxication with alcohol and/or drugs that have been self-administered 
(opportunistic DFSA) or covertly administered by the perpetrator (predatory DFSA). The drugs 
that are most commonly associated with DFSA are flunitrazepam and gamma-hydroxybutyric 
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acid (GHB). They cause sedation and amnesia, are readily dissolved in beverages and are 
rapidly eliminated from the system. However, drugs such as amphetamine and cocaine, which 
are central nervous system (CNS) stimulants, have also been encountered in DFSA cases.  
This paper critically evaluates trend data from cohort studies, identifying drugs that have been 
detected in DFSA cases and reports on the differences in drugs used between opportunistic 
and predatory DFSA. This is the first time that a critical multifactorial review of drugs used in 
DFSA has been conducted. The pharmacology of each identified group of drugs is presented, 
showing why these compounds are of interest and used in the perpetration of DFSA. 
Furthermore, the pharmacology and mechanisms of action are described to explain how the 
drugs cause their effects. It is also apparent from this study that if meaningful data is to be 
exchanged between law enforcement agencies then it is necessary to agree on protocols for 
the collection of evidence and the drugs for which analysis should be performed and indeed 
on the analytical methods used. 
 
Abbreviations 
ATS   amphetamine-type stimulants 
CNS  central nervous system 
DFC  drug-facilitated crime 
DFSA  drug-facilitated sexual assault 
GABA  gamma aminobutyric acid 
GHB  gamma hydroxybutyric acid 
GBL  gamma butyrolactone  
MDA  3,4-methylenedioxyamphetamine 
MDMA  3,4-methylenedioxymethamphetamine 
PMA  para-methoxyamphetamine 
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PMMA  para-methoxymethamphetamine 
SNRI  serotonin/norepinephrine reuptake inhibitors 
SSRI  selective serotonin reuptake inhibitors 
TCA  tricyclic antidepressants 
UNODC United Nations’ Office on Drugs and Crime 
 
Introduction 
DFSA is defined as a sexual act in which a person (female or male) is incapacitated (unable 
to give or rescind consent) due to intoxication with alcohol and/or drugs [1]. These substances 
may be self-administered by the victim (opportunistic DFSA) or administered by the offender 
(predatory/ pro-active DFSA). It is estimated that there are about half a million sexual offences 
(including DFSA) each year in England and Wales but only 1% end in convictions [2]. There 
are several factors leading to the low conviction rate - the most crucial one being low reporting 
rate. 
 
As part of the Crime Survey for England and Wales (combined data from 2007-12), 136 female 
victims (16-59 years old) of the most serious sexual offences (rape, attempted rape and sexual 
assaults by penetration) responded to a question regarding telling others about their 
experience [2]. This survey data shows that a quarter of female victims told no one about the 
sexual assault they had experienced; more than a half told someone but not the police and 
only 15% of the respondents told the police about the assault [2]. The reasons for this were 
given as feelings of self-blame, guilt, shame, embarrassment, fear, helplessness and even 
denial [2,3]. Other factors included being silenced by fear of the offender’s retaliation and not 
being believed by others, including the authorities [3].  
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The same reasons were given for male victims of sexual assaults, i.e. embarrassment and 
social stigma, as well as fear of not being believed [4]. However, lack of information on sexual 
assault on men and lack of an appropriate support system were also cited as reasons for 
under-reporting by male victims. A study published in 2016 and based on 98 male respondents 
(19 to 58 years old) to an online survey showed that even though they disagreed with the 
majority of sexual assault/penetration/rape myths, they still believed that men can defend 
themselves from sexual assault and that the police will not take it seriously if a woman sexually 
assaults a man [4].  
 
A recent study showed that some victims, who were sexually assaulted in the past and 
reported the sexual offence, expressed their unlikeliness in reporting another assault [5]. The 
reasons cited were mainly around negative experiences with the authorities and the justice 
system. Furthermore, a series of newspaper articles published in 2015 regarding a survey 
held among 1000 undergraduate students of universities across the UK reports that a third 
(33.3%) of female students and one in eight (12.5%) male students in the UK are sexually 
assaulted or abused [6].  
 
Only 10% of reported sexual assaults (i.e. 1% of all sexual assault) end in conviction in court 
[2]. Low conviction figures are attributed to a number of determinants. In some cases, it is 
impossible to identify the offender. In other cases the offender is identified but the victim 
refuses to press charges. Sometimes charges are put forward but the evidence is not sufficient 
and the charge is dismissed [2]. 
 
In DFSA cases, by the time the victim reports the case, the drug(s) has (have) cleared away 
from the system and testing of the victim’s blood and urine are of no use. Even though they 
are used to administer the drugs, the drinks themselves which are associated with such cases 
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are rarely used as evidence. It could be argued that suspected drinks should be collected and 
analysed and the knowledge of the chemical decomposition of any drug in a drink may become 
important [7]. 
 
In the Guidelines for the Forensic analysis of drugs facilitating sexual assault and other 
criminal acts published by the United Nations’ Office on Drugs and Crime (UNODC) a number 
of substances are identified as having been used to perpetrate DFSA. These include GHB, 
benzodiazepines, antihistamines, barbiturates, opioids, cannabis, cocaine, amphetamines, 
piperazines and alcohol [1]. Drugs used in DFSA need to have certain characteristics both in 
terms of how they are administered and the effect they cause on the victim including (i) causing 
sedation and/or anterograde amnesia; (ii) being odourless and tasteless; (iii) dissolving readily 
in beverages; (iv) being rapidly absorbed after oral administration, and (v) being rapidly 
cleared from the body (within 24 hours) [8].  
 
A term that is used to describe drugs associated with DFSA is “date-rape drugs”. However 
this description of substances used to spike drinks and/or food to incapacitate the victim is 
misleading as spiking is not limited to dates. 
 
In speaking to law enforcement agencies in the UK, the authors have found that there is no 
unanimous view about the analysis of suspected spiked drinks and residues in the 
investigation of alleged DFSA cases. Protocols ranged from the analysis of all types of case 
related items, including suspected spiked beverages and food as important through to relying 
on already established means (e.g. blood and urine) of evidence gathering and not regarding 
the drink residues as relevant. 
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This paper reviews the reported prevalence and use of drugs in DFSA in different countries 
for the first time bringing together and comparing data from across the globe. It then goes on 
to explain why the reported drugs may be used in such offences. Finally, recommendations 
are made as to the sources of evidential types that may be available to law enforcement agents 
and which should be considered when a scene is being investigated or an offence is thought 
to have occurred. 
 
 
Materials and Methods 
A thorough literature review was carried out to identify studies where drugs had been detected 
from a number of suspected DFSA cases. Numbers and trends were derived from the data 
presented in those studies. Besides published research articles, we also examined various 
reports from governments and other organisations (e.g. UNODC, UK’s National Health 
Service), newspaper articles, websites and other secondary sources. The data on the principle 
drugs reported to have been found in DFSA cases were collated and a comparative overview 
is provided. The mechanism of action and pharmacology of these drugs was determined to 
provide possible explanations for why these drugs may have been identified in the cases 
reported. 
 
Results and discussion 
DFSA cohort studies 
There have been a number of cohort studies that report DFSA figures and drug use [9-13] (Fig 
1).  
One of the first reports on DFSA, carried out in the USA, resulted from the analysis of urine 
samples from 3303 cases of investigated sexual assaults [9]. Urine samples were collected 
within 72 hours of the alleged incident and on arrival at the laboratory, refrigerated and 
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analysed within a week. The report found that 2026 tested positive for alcohol and/or drugs 
(Table 1). A similar cohort study was published in the United Kingdom by the Forensic Science 
Service in 2005 [10]. Their results consisted only of samples that tested positive for drugs and/ 
or alcohol both from blood and/or urine. In 2008, a study using retrospective data from 
Forensic Science Northern Ireland, collected between 1999 and 2005, was published [11]. 
The data that were taken into consideration were cases in which blood samples had been 
collected within 12 hours of the alleged sexual assault. 294 cases were investigated, 200 of 
which were positive for drugs and/or alcohol. Another study which tried to assess covert 
drugging, published in 2010, was carried out in Ontario, Canada [12]. Urine was the matrix 
which was screened for the presence of drugs. Drugs can be detected in urine samples for a 
longer time (72 h or more) in comparison with blood samples (24 – 48 h). Data was collected 
for almost two years, from June 2005 to April 2007. Of 977 people reported to have been 
sexually assaulted, about a fifth of them were suspected to be victims of DFSA (178 
participants) and 135 were positive for drug presence. A more recent study from women 
consulting at the Norwegian Sexual Assault Centre also made an attempt to estimate number 
of predatory DFSA cases [13]. This study is different to those previously described in that it 
only focussed on female victims. The data was collected between 1 July 2003 and 31 
December 2010 and 264 biological samples (urine and/or blood) were included in the study. 
 
Table 1 summarises positive results (sample tested positive for drugs and/or alcohol) of the 
five cohort studies. The USA study had the largest positive dataset, with over two thousand 
samples. Clearly, alcohol and cannabis are the two most commonly encountered substances 
in DFSA, except for Norway and Northern Ireland where benzodiazepines were featured as 
the second most detected drugs. In the USA, cocaine appeared as the second most commonly 
detected (15.4%) followed by amphetamines (13.8%) and then cannabis (10.9%). GHB, a 
compound associated with DFSA was detected in all studies except for Norway and Northern 
Ireland, even though it was included in the screening. However, due to rapid elimination of 
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GHB – the half-life of this compound ranges from 20 minutes to 1 hour [14] – it could have 
been eliminated before the sample was collected. 
 
All studies found benzodiazepines, amphetamines and opioids. The Norwegian study did not 
include antidepressants and cocaine in their screening process. Antidepressants were not 
included in the US study. This demonstrates that if data is to be exchanged on a global scale, 
an agreed set of drugs must be screened for using agreed methodologies. 
 
Opportunistic vs predatory DFSA 
Even though all suspected DFSA cases should be investigated and prosecuted with the same 
amount of diligence, it is important to distinguish between opportunistic DFSA (the victim self-
administered the substance/-s) and predatory DFSA (the perpetrator covertly administered 
the substance/-s). This distinction is made in an attempt to target compounds that are more 
likely to be used in predatory DFSA (Table 2). Furthermore, predatory DFSA implies intent on 
perpetrator’s part which is vital in criminal prosecution. In Table 2 the distinction between drugs 
in opportunistic and predatory DFSA cases, based on classifications made by the respective 
research groups, is shown. 
 
Findings from the US and Northern Ireland studies are difficult to interpret as they give no 
indication about the drug use habit of the victims, self-administration resulting in opportunistic 
DFSA or covert administration resulting in predatory DFSA. Each of the remaining research 
groups have applied different tools to identify the covert drug administration. These range from 
information obtained from police officers [10], comparison with victim’s drug use history [12] 
and victim’s suspicion of having been drugged [12,13]. 
 
In the UK study, based on information given by police officers, the authors identified only 21 
cases (2.1% of positive samples) as deliberate spiking by the perpetrator (predatory DFSA). 
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However, this number might be underestimated due to insufficient information obtained. Even 
though diazepam was the most prevalent benzodiazepine, temazepam was the drug more 
associated with deliberate drink spiking with six cases out of 12 thought to be such. Diazepam 
was only attributed to three such cases. However, temazepam is an active metabolite of 
diazepam, therefore some of the temazepam-positive samples might have been cases of the 
administered diazepam being metabolised to temazepam. Such doubt could be unravelled if 
samples of spiked beverage/ foodstuff had been collected from scene and analysed. Both 
cases in which GHB was detected, were attributed to drink spiking. Ecstasy was also found in 
three cases of suspected intentional drink spiking cases. 
 
In an Australian study published in 2006, cases in which drugs were detected but not expected 
to be there were classified as predatory DFSA [15]. 22 cases were suspected to be predatory 
DFSA cases, out of these in 15 cases unexpected drugs were detected. In five cases 
antidepressants were found, followed by cannabis, benzodiazepines, amphetamines and 
opioids (four cases each); and in one of the suspected predatory DFSA an antipsychotic was 
detected.  
 
The largest number of estimated predatory DFSA cases – 137 out of 178 – was identified in 
the Canadian study. This classification was made based on interviews, when at least one of 
the following were true: (i) the victim had no previous history of CNS active drug use and this 
type of drug had been found during analysis; (ii) the CNS active compounds found in the 
analysis were different than those declared as having been used by the participant. Almost 
half of the cases reviewed fitted the set criteria for suspected predatory DFSA (87 cases out 
of 135; 48.9% of positive samples). The drugs that had the highest scores for being 
unexpectedly found in the victims were: cannabis (35 cases; 25.9% of positive samples), 
cocaine (28 cases; 20.7% of positive samples), amphetamines (20 cases; 14.8% of positive 
samples) and opioids (20 cases; 14.8% of positive samples). Other drug groups that were 
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identified as suspected predatory DFSA cases include antihistamines (18 cases; 13.3% of 
positive samples) and benzodiazepines (13 cases; 9.6% of positive samples). Noteworthy, 
contrary to UK findings, diazepam was detected in only one case with lorazepam being the 
most prevalent benzodiazepine (4.4% of positive samples) and no data on temazepam is 
given.  
 
However, due to drug adulteration and impurities present in street samples or metabolism 
resulting in pharmacologically active metabolite (e.g. diazepam and its metabolite 
temazepam) the data acquired might be misleading in terms of identifying de facto predatory 
DFSA drugs and/or cases.  
 
According to data shown in Table 2, cocaine is associated with opportunistic DFSA, not 
predatory DFSA. This might be due to the effect that cocaine is a stimulant and therefore 
lowers inhibitions and increases libido. However, amphetamines, also CNS stimulants, were 
found in both predatory and opportunistic DFSA. Similarly, benzodiazepines were detected in 
both types of DFSA. There is no specific amphetamine type of drug that was detected in all of 
the cohort studies, whereas diazepam (prescribed in cases of anxiety, muscle spasms and 
seizures, as well as during alcohol withdrawal) was identified in all cohort studies both as a 
substance used in predatory and opportunistic DFSA.  
 
Although not as clearly, alcohol is also more likely to be found in opportunistic DFSA (Table 
2). The general scenario for a DFSA assault includes the victim being drugged and severely 
incapacitated, usually in a situation that the victim perceives as non-threatening (at a party, in 
a restaurant or club, on a date, etc.). Therefore, the presence of alcohol, in an amount that 
could incapacitate the victim, is easily explained.  
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However, it needs to be emphasised that a drug not being detected in DFSA victim’s system 
does not mean that no drugs had been administered to the victim. There are several reasons 
for this, for example, when the sample was collected for analysis, if there was a delay in 
reporting, the drug might have had already metabolised or be excreted. Another possibility is 
that the concentration of the drug present in the system was lower than the limit of detection 
set for the analytical method and/ or the extraction method was not specific. This shows the 
importance of developing a standardised method for the extraction and simultaneous 
detection of drugs from various types of evidence, including suspected spiked drinks. 
 
Why are these drugs found in DFSA cases?  
CANNABIS 
According to data from the Crime Survey for England and Wales 2014/2015 and National Drug 
Treatment Monitoring System regarding adults who received specialist substance misuse 
interventions [16,17], cannabis is the most commonly misused substance. Table 2 shows that 
cannabis is very often found in DFSA cases, even in predatory DFSA. This paints a picture of 
two scenarios of possible cannabis misuse in DFSA. Scenario one, in which the victim 
consciously agrees to participate in a gathering where cannabis is used (or food containing 
cannabis) and the perpetrator takes advantage of the situation and the victim’s reduced 
inhibitions; scenario two, in which the offender covertly administers the drug (e.g. brownies).  
 
The high prevalence of cannabis might be due to relatively easy accessibility and the 
perception that it is harmless. Cannabis can be found in three forms - marijuana, hashish and 
hash oil [18,19]. The most prevalent form – marijuana, is dried plant material that is smoked 
in a cigarette form, the so-called joint. Hashish is the resin from the dried plant, usually mixed 
with tobacco or added to food. Hash oil is a dark and viscous liquid, usually added to tobacco 
and smoked [20].  
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However, given the form in which cannabis usually appears, i.e. dried plant or resin, and its 
physical properties, i.e. dark colour and either solid or water insoluble liquid, it is less likely to 
be used to spike drinks as it does not dissolve easily in beverages. Its liquid form – hash oil, 
is soluble in water and ethanol, but due to its colour and odour it is an unlikely candidate for 
drink spiking. The onset of action for cannabis depends on the administration route, i.e. 1 – 
10 minutes when smoked and 30 – 120 minutes when administrated orally [21]. 
 
AMPHETAMINE TYPE STIMULANTS (ATS) 
Amphetamine type stimulants refers to a group of drugs that show similarities in both structure 
and pharmacological effects to (and including) amphetamine and methamphetamine [22,23]. 
ATS include amphetamines, cathinones and piperazines with the most often reported in DFSA 
being amphetamine, methamphetamine and MDMA, as well as methylphenidate, mephedrone 
and 3-CPP [1,9,10,12,13,24]. ATS, especially amphetamine and ecstasy, are the most 
commonly abused drugs among young people [25] and young adults [16]. Even though ATS 
are CNS stimulants, i.e. cause increased alertness and euphoria, they are encountered in 
DFSA as they lower inhibitions, increase susceptibility to suggestion and in some cases 
increase sex drive. Given their similar chemical structure, ATS share similar physical 
properties, which are summarised in Table 3. 
ATS pharmacology slightly varies. Half-lives range from 2 h (methylphenidate) up to 12 h 
(amphetamine). Similarly, pharmaceutical doses range from 2.5 – 25 mg for 
methamphetamine to 750 – 1000 mg for mephedrone. Onset times are more concise and 
usually do not exceed one hour. This means that it takes up to an hour for the drug to start its 
effect on the victim. For example, the time between administration of amphetamine and the 
resulting stimulation is 15-30 minutes. Detailed information is given in Table 4. 
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COCAINE 
Cocaine is another CNS stimulant encountered in DFSA which increases motor activity, 
talkativeness and euphoria, stimulating the brain’s pleasure and reward centres [32]. Although 
oral administration is possible, cocaine is usually administered nasally (by snorting) which 
produces sought behavioural changes within 15 minutes. Cocaine usually is a white powder 
but can also be in form of white lumps (crack) [27] and is soluble in both water and ethanol  
[33] and therefore meets the criteria for DFSA drink spiking.  
 
Oral administration of cocaine results in less toxicity than nasal administration due to 
hydrolysis and rapid metabolism (plasma half-life t1/2 = 0.7 – 1.5 h) [14] and onset of action is 
within minutes [21]. All major metabolites of cocaine, i.e. benzoylecgonine, ecgonine and 
ecgonine methyl ester, are pharmacologically inactive. 
 
Similar to ATS, cocaine is not an obvious candidate for DFSA due to stimulant properties. 
However, the presence of cocaine may be an indicator of the abuse of other drugs (including 
DFSA drugs) and may also suggest risk taking behaviour of the victim [34]. Cocaine can 
induce good mood (happiness, confidence, feeling energised), increased libido and 
indifference to pain [19]. These mood alterations seem to be exploited for opportunistic DFSA 
as cocaine was only detected in cases classified as opportunistic DFSA (Table 2). However, 
cocaine can also cause unpredictable, violent and aggressive behaviour.  
 
GHB and GBL 
GHB is usually encountered as a colourless liquid or crystal and is soluble in water. The effects 
of GHB, a CNS depressant, which are exploited in DFSA are: increased sex drive; lowered 
inhibitions; memory lapses; drowsiness and dizziness [19].  
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GHB is metabolised very quickly with a half-life between 20 minutes and 1 hour [14]. It is 
converted into GBL (an active metabolite). GHB is used in treatment of amnesia at a dose of 
50 mg/kg, as well as an analgesic at 10 – 20 mg. Intoxication might occur from a dose of 
15 mg/kg and doses above 50 mg/kg are considered toxic, whereas a dose of 4 g is considered 
lethal [14]. The onset times for GHB and GBL are 20 – 60 minutes and 10 – 30 minutes, 
respectively [21]. 
 
BENZODIAZEPINES 
Benzodiazepines are a group of drugs exhibiting depressant properties on CNS, having a 
sedative effect. As a result, they are used for medical purposes in treatment of anxiety and 
insomnia. Benzodiazepines most often associated with predatory DFSA are flunitrazepam and 
diazepam. Other benzodiazepines that have been associated with predatory DFSA include 
temazepam, lorazepam and nitrazepam.  
 
The properties that are applicable for DFSA exhibited by benzodiazepine intake are: 
confusion, impaired thinking and memory loss; drowsiness, sleepiness and fatigue; impaired 
coordination and dizziness [19]. Benzodiazepines are found in forms of tablets, capsules and 
injectables [27]. Benzodiazepines are lipophilic compounds and therefore less soluble in polar 
solvents such as water and ethanol. More detailed information is given in Table 5.  
 
 
There is a link between lipid solubility and onset time, i.e. the more lipid soluble the drug is, 
the faster the onset time (Table 6). Onset times range from a few minutes (e.g. lorazepam, 
nitrazepam) up to 1.5 h (e.g. diazepam, temazepam). This means that drinks spiked with 
benzodiazepines such as lorazepam and nitrazepam start acting more quickly than when 
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spiked with diazepam. Their half-lives vary from short-term acting flunitrazepam (3 h) to long-
term acting diazepam (up to 100 h). The effect of diazepam is longer than that of lorazepam. 
Toxicological data for selected benzodiazepines is given in Table 6.  
OPIOIDS  
Opioids are a class of drugs used in treatment of severe pain (pain-killers) and are represented 
by: morphine, diamorphine, codeine and methadone. Prescription-only opioid painkillers are 
the second group of drugs reportedly most commonly abused by adults [16]. Respondents of 
the 2014/2015 Crime Survey reported that the painkillers they abused were not prescribed for 
them. This shows that there is a big problem with the diverted use of prescription medications.  
Codeine is used in relief of dry irritating cough, as well as cold and flu (combined with 
antihistamines and decongestants) [19]. Methadone, on the other hand, is also used in 
treatment of opioid addiction due to its properties including: (i) it is unlikely to result in an 
overdose; (ii) the effects are long lasting which reduces the number of in-takes; (iii) it reduces 
symptoms of physical withdrawal. Effects that result from opioid intake which are exploited in 
DFSA include sedation, dizziness, sleepiness, tiredness, confusion and difficulty 
concentrating and blurred vision [19]. Opioids are available in various forms ranging from white 
powders to injectables (usually only administered in hospitals) as summarised in Table 7.  
 
Table 8 summarises pharmacological information of selected opioids. Their half-lives are 
relatively short-term, with diamorphine having the lowest half-life and a rapid onset. The 
selected opioids indicate that there is a significant difference between dosages needed for 
medical purpose, depending on the individual built up and tolerance. Methadone has the 
longest half-life and is primarily used for opioid dependence treatment. It is safer and more 
long-lasting which results in less frequent visits to the treatment centre.  
 
OTHER PHARMACEUTICAL COMPOUNDS 
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Although not as prevalent in DFSA as other drug classes, pharmaceutical compounds such 
as barbiturates, antihistamines and antidepressants have been reported.  
BARBITURATES 
Barbiturates exhibit similar pharmacological properties as benzodiazepines, with 
benzodiazepines having been introduced to replace barbiturates [27]. These include 
drowsiness and sedation as well as confusion and memory impairment. Additionally, there 
might be some residual impairment of judgment and fine motor skills the following day of 
barbiturate intake [27].  
 
Barbiturates that feature in DFSA cases include phenobarbital, pentobarbital, amobarbital, 
barbital and secobarbital and are listed by UNODC in their 2011 guidelines [1]. Barbiturates 
are still in use as medicine for treatment of insomnia, sedation and seizures, as well as 
epilepsy (e.g. phenobarbital) [27]. Similar to benzodiazepines, barbiturates are found in forms 
of tablets, capsules and injectables [27] (Table 9).  
 
Their half-lives vary from short-term acting amobarbital (8 h) to long-term acting phenobarbital 
(up to 100 h). Onset of action within barbiturates is comparable and ranges from 15 minutes 
(10 minutes for amobarbital) to 1 hour. Toxicological data for selected barbiturates is given in 
Table 10.  
 
ANTIHISTAMINES & ANTIDEPRESSANTS 
Antihistamines are medicinal compounds used most commonly in treatment of allergies. As 
they can induce sedation they have been encountered in DFSA cases (chlorpheniramine and 
diphenhydramine, i.e. first-generation antihistamines) [34]. Furthermore, antihistamines co-
administered with alcohol may have an additive pharmacological effect [34].  
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Antidepressants are compounds used in treatment of mood disorders, including depression, 
obsessive compulsive disorder and post-traumatic stress disorder [40]. Generally, 
antidepressants can be divided into following groups: selective serotonin reuptake inhibitors 
(SSRI); serotonin/norepinephrine reuptake inhibitors; tricyclic antidepressants (TCA), 
monoamine oxidase inhibitors. Antidepressants commonly encountered in DFSA are 
citalopram, an example of SSRI, and amitriptyline, an example of TCA. Antidepressants can 
impair pain signals which is why they are used in treatment of long-term pain [40]. However, 
the effects of antidepressants which are exploited in DFSA are dizziness and drowsiness, 
sleepiness and blurred vision. Antihistamines can be found in various forms including tablets, 
capsules, syrups, lotions, gels, eye drops as well as nasal sprays [41], whereas 
antidepressants usually are available as tablets (Table 11).  
Toxicological data for selected antihistamines and antidepressants is given in Table 12. Their 
half-lives vary from 2-9 h (e.g. diphenhydramine) to 33 h (citalopram).  Onset of action ranges 
from 15 minutes to 1 hour except amitriptyline and citalopram where onset is variable.  
 
Mechanisms of action  
Intercellular communication between neurones requires the release of chemical messengers 
called neurotransmitters [46]. All neurotransmitters follow a similar scheme of activity: 
1. Synthesis and storage in presynaptic neurons (the starting point of signalling); 
2. Release from the presynaptic neuron;  
3. Binding to receptors on the postsynaptic neuron (receiving end of signalling); 
4. Clearance from the synaptic cleft.  
Four groups of neurotransmitters have been defined in accordance with their structure. These 
include: (i) amino acid neurotransmitters, which participate in a wide range of signalling (e.g. 
GABA); (ii) monoamine neurotransmitters, which regulate attention, cognition and emotion 
(e.g. serotonin and dopamine); (iii) peptide neurotransmitters for pain reception (e.g. opioids); 
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and (iv) other neurotransmitters (e.g. acetylcholine) [46]. In Table 13 we discuss the 
neurotransmitters that are involved in the effects caused by drug classes associated with 
DFSA. 
 
AMINOACID NEUROTRANSMITTERS  
Benzodiazepines and barbiturates act on gamma-aminobutyric acid (GABA) receptors. GABA 
is the most common neurotransmitter in the CNS (cortex and limbic system), and reduces 
neuron excitability,  resulting in an inhibitory or calming effect [47]. There are three classes of 
GABA receptors: GABA-A, GABA-B, GABA-C [47]. Benzodiazepines bind to the GABA-A 
receptor inhibiting GABA signalling and producing a calming effect. Benzodiazepine sensitivity 
depends on the molecular constitution of the cognate receptor. The a1 subunit (present in 
60% of GABA receptors), designated as BZ1, is responsible for the sedative effect and 
anterograde amnesia, whereas the a2 isoform (BZ2) is responsible for anxiolytic and 
myorelaxant effects. The amnesic effect is enhanced with lipid solubility of the 
benzodiazepine, e.g. lorazepam which - has low lipid solubility therefore it is less likely to 
cause amnesia than other high-potency benzodiazepines (midazolam, alprazolam) [47]. 
 
Barbiturates also bind to the GABA-A receptor and alter the duration of the GABA channel 
(i.e. chloride channel) opening [49]. When barbiturates bind to the GABA channel, chloride 
ions will enter to the brain cells changing the voltage and because of this, brain cells are 
depressed. The mechanism of action of barbiturates is dose-dependent. At small 
concentrations barbiturates enhance activity of GABA. At high doses, barbiturates can activate 
GABA-A receptors without GABA being present. At higher concentrations, barbiturates inhibit 
current flow through the chloride channel.  
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A major difference in mechanism of action between benzodiazepines and barbiturates is that 
benzodiazepines bind specifically to GABA-A receptors, whereas barbiturates can also target 
other receptors in the periphery (e.g. heart) [48]. Additionally, barbiturates alter the duration of 
the chloride channel’s opening, whereas benzodiazepines modify the frequency of the 
opening [47,48].  
 
MONOAMINE NEUROTRANSMITTERS  
Drugs of abuse stimulate the brain reward pathway by triggering release of the monoamine 
neurotransmitter, dopamine. Drug use results in the generation of neuronal active potentials, 
which triggers dopamine release in synaptic clefts. Dopamine binds to receptors on the 
surface of post-synaptic neurons, resulting in signal transmission and an increase in 
pleasurable feeling. Dopamine is subsequently transported to the pre-synaptic neurons by 
dopamine transporter for their re-use. Most drugs (e.g. amphetamine, cocaine) increase the 
level of dopamine in this reward pathway resulting in a euphoric effect [49].  
 
Amphetamines are structurally similar to monoamine neurotransmitters (noradrenaline, 
dopamine and serotonin), and therefore compete with endogenous monoamines for 
monoamine reuptake transporters. At lower doses, amphetamines block transporter cells, i.e. 
reuptake of dopamine which is similar to the mechanism of action of cocaine [50]. At higher 
doses, amphetamines cause the release of more dopamine into the synapse, which 
subsequently becomes trapped, owing to prevention of dopamine reuptake.  This results in 
the build-up of dopamine, and subsequent continuous stimulation or overstimulation, resulting 
in prolonged euphoria and addiction [51]. Diamorphine also indirectly excites dopamine 
producing neurons therefore increasing the level of dopamine.  
 
Antihistamines act by competing with histamine for sites on histamine receptors [52]. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
20 
There are 4 types of histamine receptors (H1, H2, H3, H4), which differ in their tissue 
localisation and function. For example, H1 is responsible for the contraction of nonvascular 
smooth muscles and H3 inhibits the synthesis and release of histamine [53]. When activated, 
H1-receptors are stimulated resulting in improvement of learning and memory and control of 
cardiovascular system etc. [54]. Daytime release of histamine causes increased mobility and 
arousal, therefore blocking histamine receptors leads to sedation, fatigue, impaired 
concentration and memory.   
 
PEPTIDE NEUROTRANSMITTERS 
Opioids act via a family of G-protein coupled receptors, known as opioid receptors [55]. Three 
types of opioid receptors (mu, delta, and kappa) have been identified [56]. Opioid receptors 
are involved in signalling in the limbic system (emotions and feelings of pleasure), the brain 
stem (basic bodily functions, e.g. heartbeat, breath), the spinal cord (pain) and the 
hypothalamic–neurohypophyseal system (releasing of hormones/neurotransmitters) [55]. 
These receptors bind to opioid like structures (i.e. β-endorphins, enkephalins and dynorphins) 
and reduce pain perception and act in a similar manner to opiates.  
 
Opioids are also classified according to their opioid receptor action [55,57] as: 
 Agonist: morphine, diamorphine; 
 Partial agonist: buprenorphine;  
 Antagonist: naloxone.  
In the brain reward pathway, opioid receptors are stimulated by endogenous opioids (β-
endorphins). When someone uses opiates, this stimulation is caused by the drugs resulting in 
the activation of dopaminergic neurons. This results in higher levels of dopamine release 
causing euphoria.  
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Conclusion 
Substances used to spike drinks and/or food to render the victim incapacitated are commonly 
known as date-rape drugs, a term which is misleading as spiking is not limited to dates. These 
drugs exhibit specific properties which make them undetectable by the victim prior to the 
assault and afterwards by the forensic service providers. Substances commonly associated 
with DFSA are GHB and flunitrazepam (Rohypnol). However, cohort studies discussed in this 
paper show alcohol and cannabis as the most prevalent DFSA related substances, followed 
by benzodiazepines, amphetamines and opioids. Attempts have been made to distinguish 
between opportunistic and predatory DFSA drugs. Amphetamines and benzodiazepines as 
well as cannabis and opioids have been identified as drugs used for both predatory and 
opportunistic DFSA, whereas alcohol and cocaine as substances more likely to be self-
administered by the victim. The pharmacology and mechanism of action of these different drug 
groups is presented to explain their effects and application in DFSA. 
 
Due to the properties that the DFSA drugs exhibit, most of them are CNS depressants, i.e. 
they cause sedation, confusion and loss of consciousness. However, CNS stimulants such as 
amphetamines and cocaine have also been identified in DFSA as they lower inhibitions and 
increase sex drive, as well as make the person who took them more susceptible to suggestion. 
This paper provided a review of drugs reportedly associated with DFSA and critically 
discussed key properties of these substances which may result in them being identified as 
part of the investigation in DFSA cases. 
 
Given that by the time the victim reports the assault, time will have passed and testing of the 
victim’s blood and urine might lead to a negative result as the drug will have been metabolised 
and cleared from the body. Even though the drinks are entry points for the drugs, the drinks 
themselves are rarely ever used as evidence in DFSA cases as they are rarely collected since 
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when the victim reports 1) they may not know where the drug was administered, 2) it was in a 
public place (pub or club) and the glasses/ bottles would have been cleared or there is no way 
to identify the specific vessel, 3) the suspect has cleared and washed all drinking vessels. 
Consequently, the analysis of suspected drinks (in cases where they are collected) and 
knowledge of the behaviour of a drug in a drink becomes important as this provides useful 
information on any drugs used in the alleged assault. Therefore, it is recommended that a 
standard set of drugs should be screened for using a standard, harmonised, battery of 
screening techniques if data is to be exchanged around the drugs used in DFSA between 
different law enforcement agencies. 
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Fig 1. Distribution of samples (cases; positive and negative) in suspected drug facilitated 
sexual assault cases from US, UK, Canada, Northern Ireland and Norway [9-13].  
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Table 1. Drug prevalence in reviewed DFSA cases. 
 
USA UK 
Northern 
Ireland 
Canada Norway 
No. of positive 
samples 
2026 1014 200 135 155 
Alcohol 1358 67.0% 470 46.4% 98 49.0% 55 40.7% 119 76.8% 
Cannabis 613 10.9% 260 25.6% 23 11.5% 60 44.4% 13 8.4% 
Benzodiazepines 313 2.0% 84 8.3% 37 18.5% 20 14.8% 46 29.7% 
Cocaine 279 15.4% 110 10.8% 3 1.5% 38 28.1% Not included 
Amphetamines 220 13.8% 70 6.9% 12 6.0% 26 19.2% 16 10.3% 
Opioids 131 6.5% 103 10.2% 37 18.5% 24 17.8% 14 9.0% 
GHB 100 4.9% 2 0.2% 0 0 2 1.5% 0 0 
Antidepressants Not included 74 7.3% 12 6.0% 29 21.5% Not included 
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Table 2. Distribution of estimated predatory and opportunistic drug facilitated sexual assault cases based 
on data from Australia, UK, Canada and Norway ( indicates that the substance was classified in the group; 
 indicates that the substance was not classified in the group) [10,12,13,15].  
 Predatory Opportunistic 
 UK AUS Canada Norway UK AUS Canada Norway 
Alcohol      
n
o
 d
a
ta
 a
v
a
ila
b
le
 
  
Cannabis        
Benzodiazepines        
Cocaine        
Amphetamines        
GHB        
Opioids        
Barbiturates        
Antihistamines        
Antidepressants        
Ketamine        
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Table 3. Physical forms of selected ATS [19,26,17] and their solubility ( : soluble).  
Compound Form  
Solubility 
Water Ethanol 
A
m
p
h
e
ta
m
in
e
s
 Amphetamine 
powder; tablets; crystals; capsules 
colour ranges from white to brown (including grey 
and pink) 
  
Methamphetamine 
clear crystals 
white or brownish crystal-like powder 
  
MDMA 
white or off-white powder 
tablets, capsules or crystals in various colours 
  
C
a
th
in
o
n
e
s
 
Cathinones 
(general) 
Mephedrone 
white or brown amorphous or crystalline powder; 
capsules, pills 
white powder with a slight trace of yellow 
  
Piperazines (general) tablets, capsules; powder   
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Table 4. Half-life, onset and applied doses for selected ATS drugs [14,21,27-31]. 
Compound 
Onset  
[min] 
Half-
life 
[h] 
Major metabolites 
Dose 
Pharmaceutical/ 
therapeutic 
Toxic 
A
m
p
h
e
ta
m
in
e
s
 Amphetamine 15 – 30 
12 
(4 – 8 h 
if urine 
pH < 7) 
1-phenyl-2-propanone 
(active);  
4-hydroxyamphetamine 
(active) 
20-100 mg 
(treatment of 
narcolepsy) 
200 
mg  
Meth-
amphetamine 
20 – 70 9 
4-hydroxymethamphetamine 
(active);  
amphetamine (active) 
2.5 – 25 mg 1 g 
MDMA 20 – 70 6 – 7 MDA (active) 80 – 200 mg 
300 
mg 
C
a
th
in
o
n
e
s
 
Mephedrone 15 – 45 2 
 nor‐mephedrone (active);  
4‐OH‐mephedrone (active); 
dihydromephedrone (active) 
from 100 – 
250 mg up to 
750 - 1000 mg 
NA 
P
ip
e
ra
z
in
e
s
 
3-CPP 20 – 60 4.5 
hydroxy-mCPP (active);  
N-(3-
chlorophenyl)ethylenediamin
e (inactive); 
 3-chloroaniline; 
hydroxy-3-chloroaniline 
(inactive) 
8 – 80 mg NA 
NA = not available 
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Table 5. Physical properties of selected benzodiazepines and their solubility [14,27,35]. 
Compound Form 
Solubility 
Water Ethanol 
Diazepam 
Tablets, capsules, 
injectables 
Slightly soluble Soluble 
Flunitrazepam Sparingly soluble Slightly soluble 
Lorazepam Insoluble Sparingly soluble 
Nitrazepam Practically insoluble Slightly soluble 
Temazepam 
Practically insoluble/ very slightly 
soluble 
Soluble/ freely 
soluble 
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Table 6. Half-life, onset and applied doses for selected benzodiazepines (toxic doses are not known) 
[14,21,27]. 
Compound 
Onset 
[min] 
Half-life 
[h] 
Major metabolites 
Pharmaceutical/ 
therapeutic dose 
Diazepam 30 – 90 20 – 100 
Desmethyldiazepam (active); 
oxazepam (active); 
temazepam (active) 
5 – 30 mg 
Flunitrazepam 15 – 30 16 – 35 
Desmethylflunitrazepam 
(moderately active) 
7-aminoflunitrazepam 
(inactive) 
0.5 – 2 mg 
Lorazepam 5 – 30 9 – 24 
Glucuronide conjugate of 
lorazepam (inactive) 
1 – 10 mg 
Nitrazepam 10 – 40 18 – 38 
7-aminonitrazepam (inactive);  
7-acetoamidonitrazepam 
(inactive) 
5 – 10 mg 
Temazepam 20 – 90 8 – 15 
Glucuronide conjugate of 
temazepam (inactive) 
1 – 20 mg (insomnia);  
20 – 40 mg 
(premedication) 
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Table 7. Physical forms of selected opioids and their solubility [14,19,35,36]. 
Compound Form 
Solubility 
Water Ethanol 
Morphine 
Tablets, capsules, suppositories; injectables 
(only in hospitals) 
Very slightly 
soluble 
Slightly 
soluble 
Diamorphine 
Fine white powder; off-white granules; light 
brown lumps 
Very slightly 
soluble 
Sparingly 
soluble 
Codeine Tablets; capsules; suppositories; liquids Slightly soluble Freely soluble 
Methadone 
Syrup (opioid addiction); injection and tablets 
(pain relief) 
Soluble Freely soluble 
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Table 8. Half-lives and applied doses for selected opioids [14,21,37,38]. 
Compound 
Onset  
[min] 
Half-
life 
[h] 
Major metabolites 
Dose 
Pharmaceutical/ 
therapeutic 
Toxic 
Morphine 15 – 60 2 – 3 
Morphine 3-glucuronides 
(active); morphine 6-
glucuronides (active); 
normorphine (active); 
codeine (active); morphine 
ethereal sulphate (active) 
5 – 20 mg 
200 mg but 
higher in 
addicts 
Diamorphine 
Not 
available 
3 min 
INTRAVENOUS 
ADMINISTRATION 
6-monoacetylmorphine 
(active); normorphine (active) 
ORAL ADMINISTRATION 
morphine (active) 
5 – 10 mg 
(intravenous 
administration) 
50 – 70 mg (oral 
administration) 
 
From 200 mg 
(no 
dependence) 
up to 10 g 
(high 
tolerance) 
Codeine 30 – 45  2 – 4 
Morphine (active); 
norcodeine (relatively 
inactive) 
30 – 60 mg 800 mg 
Methadone 45 – 120 
10 – 
25 
2-ethylidene-1,5-dimethyl-
3,3-diphenylpyrolidine 
(inactive);  
2-ethyl-5-methyl-3,3-
diphenylpyrroline (inactive) 
2.5 – 10 mg, up 
to 30 mg (pain 
relief);  
10 – 60 mg 
(opioid 
dependence) 
50 mg; 200 
mg and 
higher for 
addicts 
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Table 9. Physical properties of selected barbiturates and their solubility [14,27]. 
Compound Form 
Solubility 
Water Ethanol 
Amobarbital 
Tablets, capsules, injectables 
Very slightly soluble Freely soluble 
Barbital Slightly soluble  Soluble 
Pentobarbital Very slightly soluble Freely soluble 
Phenobarbital Slightly soluble Freely soluble 
Secobarbital Very slightly soluble Freely soluble 
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Table 10. Half-lives and applied doses for selected barbiturates [14,21,27,39]. 
Compound 
Onset  
[min] 
Half-life 
[h] 
Major metabolites 
Dose 
Pharmaceutical/ 
therapeutic 
Toxic 
Amobarbital 10 – 30 8 – 40 
3’-hydroxyamobarbital 
(moderately active) 
30 – 240 mg 
1.5 g 
(lethal) 
Barbital 15 – 30 48 
Excreted almost entirely as 
unchanged drug 
300 – 600 mg 
2 g 
(lethal) 
Pentobarbital 15 – 60 15 – 50 
(1′S,3′R)-, (1′S,3′S)-, 
(1′R,3′S)-, and (1′R,3′S)-5-
ethyl-5-(3′-hydroxy-1′-
methylbutyl)barbituric acids 
(relatively inactive) 
100 mg (as 
hypnotic) 
1 g 
(lethal) 
Phenobarbital 15 – 45 
90 – 100 
(adults) 
65 – 70 
(children) 
N-
glucopyranosylphenobarbital 
(inactive); 4-
hydroxyphenobarbital 
(inactive); glucuronide 
conjugate of phenobarbital 
(inactive) 
60 – 180 mg 
1.5 g 
(lethal) 
Secobarbital 15 – 30 19 – 34 
Hydroxylation of both side-
chains at the C5-position 
with further oxidation of the 
omega-position on the butyl 
side-chain (inactive) 
100 mg 
2g 
(lethal) 
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Table 11. Physical properties for selected antihistamines and antidepressants [35,41]. 
 
Compound Form 
Solubility 
Water Ethanol 
A
n
ti
d
e
p
re
s
s
a
n
ts
 Amitriptyline  
(as hydrochloride salt) 
Tablets 
Freely 
soluble 
 Freely soluble 
Citalopram 
(as hydrochloride salt) 
Tablets, drops 
Very 
soluble 
Freely soluble in 
anhydrous ethanol 
Citalopram 
(as hydrobromide salt) 
Sparingly 
soluble 
Sparingly soluble in 
anhydrous ethanol 
A
n
ti
h
is
ta
m
in
e
s
 Chlorpheniramine  
(as maleate salt) 
Tablets, capsules, syrups, 
lotions, gels, eye drops as well 
as nasal sprays 
Freely 
soluble 
Soluble 
Diphenhydramine  
(as hydrochloride salt)  
Very 
soluble 
Freely soluble 
Promethazine  
(as hydrochloride salt) 
Very 
soluble 
Freely soluble 
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Table 12. Half-lives and applied doses for selected antihistamines and antidepressants [14,21,27,42-45]. 
Compound 
Onset 
[min] 
Half-life 
[h] 
Major metabolites 
Dose 
Pharmaceutical/ 
therapeutic 
Toxic 
Amitriptyline variable 
9 – 26 
(higher in 
cases of 
overdose) 
Nortriptyline (active) 
50 – 150 mg  
max. 300 mg 
1 g 
(intoxication) 
2 g 
(severely 
toxic/ lethal) 
Citalopram variable 
33  
(3.75 
days in 
elderly) 
desmethylcitalopram 
(moderately active), 
didesmethylcitalopram 
(moderately active), 
citalopram-N-oxide 
(moderately active), 
propionic acid 
derivative (moderately 
active) 
20 mg – 60 mg Not know  
Chlorpheniramine 30 – 60 2 – 43 
Monodesmethyl and 
didesmethyl 
metabolites (inactive) 
8 – 12 mg 
25 – 50 
mg/kg 
(lethal) 
Diphenhydramine 15 – 60 2 – 9 
Monodesmethyl and 
didesmethyl 
metabolites (inactive) 
75 – 200 mg 3 g (lethal) 
Promethazine 15 – 30 10 – 15 
Promethazine 
sulfoxide (inactive) 
20 – 100 mg 
200 mg/kg 
(lethal) 
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Table 13. Overview of mechanism of action for drugs targeting neurotransmitters [47- 49,52,55,58]. 
Neurotransmitter 
type 
Drugs Properties Mechanism of action 
Monoamine Amphetamines  CNS 
stimulant 
Low dose: blockage of transporter 
cells i.e. reuptake of dopamine 
High dose: high level of dopamine is 
released from cell leading to high level 
of dopamine in synapse 
Cocaine  CNS 
stimulant 
Blockage of transporter cells resulting 
in high level of dopamine in synapse.  
Diamorphine  Narcotics Indirectly excites dopamine 
Antihistamines  Sedative Blocking histamine action on receptor 
GABA Benzodiazepines and 
barbiturates  
CNS 
depressants 
Inducing the inhibitory effect of GABA 
Peptide  Opioids CNS 
depressants 
Interaction with the opiate receptors to 
reduce pain perception 
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